Haisco Pharmaceutical Group Co., Ltd.
002653
Rank in Stocks
#2069
Haisco Pharmaceutical Group Co., Ltd., along with its subsidiaries, operates... Haisco Pharmaceutical Group Co., Ltd., along with its subsidiaries, operates within China, focusing on the research, production, and distribution of a diverse range of pharmaceutical products. Their offerings span various dosage forms, including small and large volume injections, freeze-dried and conventional powder injections, and active pharmaceutical ingredients (APIs). These medications target numerous therapeutic areas such as anti-infectives, digestive system disorders, blood system conditions, nervous system ailments, parenteral nutrition, antibiotics, emergency care, anesthesiology, and oncology. Furthermore, the company provides drugs in tablet, capsule, granule, and ointment forms for cardiovascular health, infectious diseases, digestive issues, central nervous system (CNS) conditions, diabetes, and hepatic diseases. Established in 2000 and based in Shannan, China, the company adopted its current name, Haisco Pharmaceutical Group Co., Ltd., in March 2016, having previously been known as Xizang Haisco Pharmaceutical Group Co., Ltd.
Share Price
$8.74
Market Cap
$9.97B
Change (1 day)
1.17%
Change (1 year)
20.15%
Country
CN
Trade Haisco Pharmaceutical Group Co., Ltd. (002653)
Category
Healthcare
P/E ratio for Haisco Pharmaceutical Group Co., Ltd. (002653)
P/E ratio as of October 2026 TTM: 63.52
According to Haisco Pharmaceutical Group Co., Ltd. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 63.52. At the end of 2023 the company had a P/E ratio of 89.26.
P/E ratio history for Haisco Pharmaceutical Group Co., Ltd. from 2008 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 63.52 | -32.54% |
| 2024 | 94.16 | 5.49% |
| 2023 | 89.26 | 46.07% |
| 2022 | 61.11 | 44.00% |
| 2021 | 42.44 | 44.17% |
| 2020 | 29.44 | -33.24% |
| 2019 | 44.09 | 20.81% |
| 2018 | 36.50 | -23.67% |
| 2017 | 47.82 | 29.49% |
| 2016 | 36.93 | -40.96% |
| 2015 | 62.54 | 53.26% |
| 2014 | 40.81 | -0.92% |
| 2013 | 41.19 | 65.72% |
| 2012 | 24.85 | 13.76% |
| 2011 | 21.85 | 0.00% |
| 2010 | 21.85 | -3.45% |
| 2009 | 22.63 | -30.95% |
| 2008 | 32.77 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | -54.69% |
US
|
|
| -28.36 | -144.64% |
US
|
|
| -24.57 | -138.67% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -52.25% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.